Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 4/2016

01-04-2016 | Original Article

Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density

Authors: C. Ma, B. Shuai, L. Shen, Y. P. Yang, X. J. Xu, C. G. Li

Published in: Osteoporosis International | Issue 4/2016

Login to get access

Abstract

Summary

Many epidemiological studies have shown that in some tumors carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and β-catenin appear to be related. However, it remains to be established whether CEACAM1 is related to β-catenin in osteoporosis. Here, we reveal that CEACAM1 might influence the canonical Wnt/β-catenin pathway to modulate bone metabolism in postmenopausal osteoporosis.

Introduction

The aim of this study is to assess the serum level of CEACAM1 in postmenopausal women and its correlation with β-catenin and bone mineral density (BMD).

Methods

The BMD was measured at the lumbar spine (L1–L4) or the femoral neck using dual-energy X-ray absorptiometry (DXA). Serum CEACAM1, β-catenin, receptor activator of nuclear factor kappa-B (RANKL), osteoprotegerin (OPG), β-isomerized C-terminal crosslinking of type I collagen (β-CTX), intact N-terminal propeptide of type I collagen (PINP), estradiol, and insulin were measured in 350 postmenopausal women. Patients were divided according to lumbar spine or femur neck T-scores into osteoporosis (group I), osteopenia (group II), and normal bone mineral density, the latter serving as control.

Results

Serum CEACAM1 levels were significantly lower in group I and II compared to those in control subjects (P < 0.001). Serum CEACAM1 levels correlated positively with β-catenin and BMD, but correlated negatively to the ratio between RANKL and OPG.

Conclusion

This study provides evidence that decreased serum CEACAM1 levels are related to low BMD in postmenopausal women, and that serum CEACAM1 levels correlated positively to β-catenin. It suggests that CEACAM1 might influence the canonical Wnt/β-catenin pathway to modulate bone metabolism.
Literature
1.
2.
McClung MR (2003) The menopause and HRT. Prevention and management of osteoporosis. Best Pract Res Clin Endocrinol Metab 17:53–71CrossRefPubMed
3.
McNamara LM (2010) Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 7:353–372CrossRefPubMed
4.
Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M (2011) Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-kappaB and MAPK signaling pathways. J Bone Miner Res 26:644–656CrossRefPubMed
5.
Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635–2643CrossRefPubMed
6.
7.
Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57:272–276CrossRefPubMed
8.
Xu XJ, Shen L, Yang YP, Zhu R, Shuai B, Li CG, Wu MX (2013) Serum beta-catenin levels associated with the ratio of RANKL/OPG in patients with postmenopausal osteoporosis. Int J Endocrinol 2013:534352PubMedPubMedCentral
9.
Jin L, Li Y, Chen CJ, Sherman MA, Le K, Shively JE (2008) Direct interaction of tumor suppressor CEACAM1 with beta catenin: identification of key residues in the long cytoplasmic domain. Exp Biol Med (Maywood) 233:849–859CrossRef
10.
Chen D, Iijima H, Nagaishi T, Nakajima A, Russell S, Raychowdhury R, Morales V, Rudd CE, Utku N, Blumberg RS (2004) Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function. J Immunol 172:3535–3543CrossRefPubMed
11.
Singer BB, Scheffrahn I, Obrink B (2000) The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. Cancer Res 60:1236–1244PubMed
12.
Heckt T, Bickert T, Jeschke A, Seitz S, Schulze J, Ito WD, Zimmermann W, Amling M, Schinke T, Horst AK, Keller J (2014) Increased osteoclastogenesis in mice lacking the carcinoembryonic antigen-related cell adhesion molecule 1. PLoS ONE 9, e114360CrossRefPubMedPubMedCentral
13.
Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, Yoneda T (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 96:1953–1960PubMed
14.
Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98:11581–11586CrossRefPubMedPubMedCentral
15.
Tanaka Y, Maruo A, Fujii K, Nomi M, Nakamura T, Eto S, Minami Y (2000) Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: characteristic involvement of cell cycle regulators. J Bone Miner Res 15:1912–1923CrossRefPubMed
16.
17.
Eslami B, Zhou S, Van Eekeren I, LeBoff MS, Glowacki J (2011) Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int 88:272–280CrossRefPubMedPubMedCentral
18.
Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N, Gregory CA (2010) Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci U S A 107:4147–4152CrossRefPubMedPubMedCentral
19.
Johnson ML, Kamel MA (2007) The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 19:376–382CrossRefPubMed
20.
Case N, Ma M, Sen B, Xie Z, Gross TS, Rubin J (2008) Beta-catenin levels influence rapid mechanical responses in osteoblasts. J Biol Chem 283:29196–29205CrossRefPubMedPubMedCentral
21.
Zhang R, Oyajobi BO, Harris SE, Chen D, Tsao C, Deng HW, Zhao M (2013) Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 52:145–156CrossRefPubMed
22.
Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL (2006) Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 21:910–920CrossRefPubMed
23.
Borchert KM, Galvin RJ, Frolik CA, Hale LV, Halladay DL, Gonyier RJ, Trask OJ, Nickischer DR, Houck KA (2005) High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay Drug Dev Technol 3:133–141CrossRefPubMed
24.
Price MA (2006) CKI, there's more than one: casein kinase I family members in Wnt and hedgehog signaling. Genes Dev 20:399–410CrossRefPubMed
25.
26.
Huang SKMHM (2010) Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 46:1138–1145CrossRefPubMedPubMedCentral
27.
Poy MN, Ruch RJ, Fernstrom MA, Okabayashi Y, Najjar SM (2002) Shc and CEACAM1 interact to regulate the mitogenic action of insulin. J Biol Chem 277:1076–1084CrossRefPubMed
28.
Kuespert K, Pils S, Hauck CR (2006) CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 18:565–571CrossRefPubMed
29.
30.
31.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176CrossRefPubMed
32.
Mulcahy LE, Taylor D, Lee TC, Duffy GP (2011) RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. Bone 48:182–188CrossRefPubMed
33.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed
34.
Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251–264CrossRefPubMed
35.
Kung AW, Fan T, Xu L, Xia WB, Park IH, Kim HS, Chan SP, Lee JK, Koh L, Soong YK, Soontrapa S, Songpatanasilp T, Turajane T, Yates M, Sen S (2013) Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 13:7CrossRefPubMedPubMedCentral
36.
Riggs BL, Khosla S, Melton LR (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302CrossRefPubMed
37.
Wang JL, Sun SZ, Qu X, Liu WJ, Wang YY, Lv CX, Sun JZ, Ma R (2011) Clinicopathological significance of CEACAM1 gene expression in breast cancer. Chin J Physiol 54:332–338CrossRefPubMed
38.
Hyder SM, Nawaz Z, Chiappetta C, Stancel GM (2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60:3183–3190PubMed
39.
Ergun S, Kilik N, Ziegeler G, Hansen A, Nollau P, Gotze J, Wurmbach JH, Horst A, Weil J, Fernando M, Wagener C (2000) CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 5:311–320CrossRefPubMed
Metadata
Title
Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density
Authors
C. Ma
B. Shuai
L. Shen
Y. P. Yang
X. J. Xu
C. G. Li
Publication date
01-04-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 4/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3408-3

Other articles of this Issue 4/2016

Osteoporosis International 4/2016 Go to the issue

Review Article

Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis

Original Article

Association of osteoporosis with genetic variants of circadian genes in Chinese geriatrics

Erratum

Erratum to: The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations

Editorial

Achieving the protection of high peak bone mass

Original Article

A combination of low serum concentrations of vitamins K1 and D is associated with increased risk of hip fractures in elderly Norwegians: a NOREPOS study

Short Communication

Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data